Literature DB >> 23064668

[Kala azar - Lethal course of visceral leishmaniasis. Synchronous infection with Leishmania donovani/infantum complex and Leishmania major in a patient after Mediterranean vacation].

C Posch1, J Walochnik, A Gschnait, H Feichtinger, K Rappersberger.   

Abstract

BACKGROUND: Infections with Leishmania spp. are endemic in areas of the tropics and subtropics. An increased incidence of human infections has been reported in southern Europe, where zoonotic leishmaniasis is common. The systemic, visceral infection is caused by the Leishmania donovani/infantum complex and may be fatal when untreated. PATIENT AND METHODS: A 42-year-old man presented with a 6 week history of erythroderma, pancytopenia, hepatosplenomegaly and recurrent fever after a sojourn in Croatia. The patient's past history revealed a 10-year history of psoriasis and chronic obstructive pulmonary disease treated with methotrexate and prednisolone. Pathology was assessed by histology and molecular biologic analyses. RESULTS AND COURSE: A repeated bone marrow biopsy revealed multiple intracellular particles which were identified as Leishmania amastigotes. Indirect immunofluorescence as well as enzyme-linked immunosorbent assay (ELISA) of patient's serum showed specific anti-Leishmania antibodies. Despite rapid initiation of systemic therapy, the patient died of a secondary infection. Post mortem, PCR and sequencing revealed synchronous infection with Leishmania donovani/infantum complex and Leishmania major.
CONCLUSIONS: Diagnosis of patients with complex clinical features is challenging even for experienced clinicians. Critical interpretation of findings and, if necessary, repetition of invasive examinations may be necessary for proper diagnosis. Increasing numbers of immunocompromised patients (iatrogenic, HIV) will expand the spectrum of rare infectious diseases including visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064668     DOI: 10.1007/s00105-012-2446-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  27 in total

Review 1.  Leishmaniasis: prevention, parasite detection and treatment.

Authors:  T Kobets; I Grekov; M Lipoldova
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

3.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

4.  Treatment of visceral leishmaniasis.

Authors:  E M Moore; D N Lockwood
Journal:  J Glob Infect Dis       Date:  2010-05

5.  Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh.

Authors:  Dinesh Mondal; Kamrul Nahar Nasrin; M Mamun Huda; Mamun Kabir; Mohammad Shakhawat Hossain; Axel Kroeger; Tania Thomas; Rashidul Haque
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

Review 6.  Leishmaniasis.

Authors:  Tonio V Piscopo; Charles Mallia Azzopardi
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

7.  Development of a molecular assay specific for the Leishmania donovani complex that discriminates L. donovani/Leishmania infantum zymodemes: a useful tool for typing MON-1.

Authors:  Christos Haralambous; Maria Antoniou; Francine Pratlong; Jean-Pierre Dedet; Ketty Soteriadou
Journal:  Diagn Microbiol Infect Dis       Date:  2007-09-21       Impact factor: 2.803

8.  Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas?

Authors:  M Weisser; B Khanlari; L Terracciano; C Arber; A Gratwohl; S Bassetti; C Hatz; M Battegay; U Flückiger
Journal:  Clin Microbiol Infect       Date:  2007-08       Impact factor: 8.067

9.  Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis.

Authors:  Ambak K Rai; Chandreshwar P Thakur; Amar Singh; Tulika Seth; Sandeep K Srivastava; Pushpendra Singh; Dipendra K Mitra
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

10.  Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis.

Authors:  Pramod Kumar Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

View more
  1 in total

Review 1.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.